Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
This robust growth has come despite the raging pandemic for most part of the quarter
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
It is part of the company’s pain/analgesics portfolio of OTC products
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
Subscribe To Our Newsletter & Stay Updated
